pocketful logo
Lincoln Pharmaceuticals Ltd logo

Lincoln Pharmaceuticals Ltd

NSE: LINCOLN BSE: 531633

654.30

(6.25%)

Fri, 13 Feb 2026, 03:47 pm

Lincoln Pharmaceuticals News

Lincoln Pharma Q3FY26 Net Profit Surges 37.70% YoY

Lincoln Pharmaceuticals reports consolidated net profit of ₹28.60 crore in Q3FY26, up 37.70% YoY. Revenue from operations grows 13.49% to ₹166.32 crore with strong performance across therapeutic segments.

12 Feb 2026

co actions results

Lincoln Pharmaceuticals Gets CRISIL A/Stable Rating

Lincoln Pharmaceuticals receives credit rating reaffirmation from CRISIL with long-term facilities at CRISIL A/Stable and short-term at CRISIL A1, reflecting strong financial profile.

10 Jan 2026

stocks

Lincoln Pharmaceuticals Reports 24% Drop in Q2 Net Profit Despite Revenue Stability

Lincoln Pharmaceuticals reported a consolidated net profit of Rs. 20.01 crore for Q2FY26, down 24.06% year-on-year, while total income remained stable at Rs. 170.60 crore with only a 0.34% decline. The company targets Rs. 1,000 crore revenue within three years and aims for 15-18% annual growth, driven by expansion in cardiac, diabetic, dermatology, and ENT segments.

13 Nov 2025

earnings

Lincoln Pharma Reports 17% Net Profit Growth in Q1 Results

Lincoln Pharmaceuticals reported net profit of Rs 27.70 crore for the April-June quarter, marking a 17% increase from Rs 23.69 crore in the same period last year. Total income grew 7.3% to Rs 169.34 crore compared to Rs 157.69 crore in the previous year. EBITDA rose 17.92% to Rs 39.08 crore from Rs 33.14 crore year-on-year. The company targets Rs 1,000 crore revenue within three years through business expansion into high-value product lines and new markets, aiming for 15-18% annual growth driven by cardiac, diabetic, dermatology, and ENT segments. During the quarter, the company launched its bulk drug manufacturing plant with Rs 4 crore investment from internal funds and received approvals for 10 products. Company shares surged 8.47% to close at Rs 576.90 on BSE.

07 Aug 2025

earnings

Lincoln Pharmaceuticals Re-appoints Four Key Directors for Five-Year Terms

Lincoln Pharmaceuticals Limited's Board of Directors approved the re-appointment of four senior executives for five-year terms, subject to shareholder approval at the upcoming Annual General Meeting. Mahendra G. Patel was re-appointed as Managing Director from October 1, 2025 to September 30, 2030. Three Whole Time Directors were also re-appointed: Hashmukh I. Patel for the same October 2025 to September 2030 period, while Ashish R. Patel and Munjal M. Patel will serve from November 14, 2025 to November 13, 2030. The appointments were recommended by the Nomination and Remuneration Committee. Mahendra G. Patel, a law graduate with over 45 years of pharmaceutical industry experience, has served as Managing Director since the company's incorporation and is a company promoter. Hashmukh I. Patel, a science graduate with three decades of pharma experience, manages domestic marketing and sales distribution. Ashish R. Patel holds an MBA in Marketing from the UK and handles marketing operations and sales strategies. Munjal M. Patel has a Master's degree in Finance from the USA with over 10 years of pharma experience and manages international trade and financial matters.

07 Aug 2025

corporate governance

Showing 15 of 15
Rows per page:

Market Current News

RUPA & COMPANY LTD. logo

RUPA & COMPANY LTD.

Rupa & Company Q3FY26 Results & Leadership Change

Rupa & Company reported Q3FY26 net profit of ₹1,610.39 lakhs with revenue of ₹31,359.67 lakhs. Company Secretary Sumit Jaiswal resigned effective February 28, 2026.

12 Feb 2026

co actions results

RUPAREL FOOD PRODUCTS LIMITED logo

RUPAREL FOOD PRODUCTS LIMITED

Ruparel Food Products Reports Q3FY26 Loss

Ruparel Food Products Limited reported a net loss of ₹1.66 lakhs for Q3FY26 with revenue of ₹87.57 lakhs. Nine-month loss widened to ₹9.79 lakhs despite revenue growth to ₹320.74 lakhs.

12 Feb 2026

co actions results

RENAISSANCE GLOBAL LIMITED logo

RENAISSANCE GLOBAL LIMITED

Renaissance Global Q3FY26 Results Show Strong Recovery

Renaissance Global Limited reported consolidated revenue of ₹96,294.23 lakhs in Q3FY26, up from ₹54,636.31 lakhs in Q2FY26. Net profit reached ₹3,320.98 lakhs for the quarter.

12 Feb 2026

co actions results

IIFL FINANCE LIMITED logo

IIFL FINANCE LIMITED

IIFL Finance Announces ₹2,000 Cr NCD Public Issue

IIFL Finance Limited announces public issue of secured NCDs worth up to ₹2,000 crores with base size of ₹500 crores. Finance Committee approved the issue on February 12, 2026.

12 Feb 2026

co actions results

STARLINEPS ENTERPRISES LIMITED logo

STARLINEPS ENTERPRISES LIMITED

Starlineps Enterprises writes off Rs 529.36 lacs

Starlineps Enterprises Limited announces write-off of Rs 529.36 lacs from Capital Work-in-progress following Audit Committee recommendation and Board approval on February 12, 2026.

12 Feb 2026

stocks

Showing 15 of 84199
Rows per page:

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800